search
Back to results

SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study

Primary Purpose

COVID-19

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Text-Messaging (TM)
Patient Navigation (PN)
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for COVID-19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • current patient of a participating community health center
  • have a working cellphone,
  • have phone number listed in existing electronic medical record at their participating clinic
  • speak English or Spanish.

Exclusion Criteria:

- Minors

Sites / Locations

  • University of Utah

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Text Messaging (TM) + No Patient Navigation

Text Message (TM) + Request (RPN)

Arm Description

Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed. Patients will not receive patient navigation.

Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed. RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination.

Outcomes

Primary Outcome Measures

Testing
Proportion of patients who use the at-home test out of those exposed to the intervention

Secondary Outcome Measures

Time-To-Vaccine
Time to event outcome
Reach-Engage Testing
Proportion of patients that reply to an offer to receive an at-home rapid test kit
Reach-Accept Testing
Proportion of patients that accept an offer to receive an at-home test kit
Reach-Engage Vaccine
Proportion of patients that reply to an offer to receive a vaccine
Reach- Accept Vaccine
Proportion of patients that accept an offer to receive a vaccine

Full Information

First Posted
September 7, 2022
Last Updated
September 22, 2023
Sponsor
University of Utah
Collaborators
Utah Department of Health, Association for Utah Community Health, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT05533918
Brief Title
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study
Official Title
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Testing and Vaccination Among Utah Community Health Centers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 15, 2022 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah
Collaborators
Utah Department of Health, Association for Utah Community Health, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations. Through RADx-UP Phase I funding (SCALE-UP Utah), the team has established population health management (PHM) interventions that have been used since Feb 2021 to increase the uptake of COVID-19 testing and vaccination among community health center patients. Interventions are based on a PHM approach that uses widely available technology (i.e. cell phones and text messaging). SCALE-UP II will both build on SCALE-UP Utah PHM interventions and investigate novel resource conservation approaches (i.e., Request-Patient Navigation vs. No Patient Navigation and text messaging vs. conversational agent). SCALE-UP II builds on long standing partnerships among the University of Utah Clinical and Translational Science Institute (UofU CTSI), Association for Utah Community Health (AUCH), CHCs, and the Utah Department of Health(UDOH). CTSI and SCALE-UP II investigators are leading several COVID-19 initiatives that drive public health response and state government policies in Utah.
Detailed Description
Racial/ethnic minority, low socioeconomic status (SES), and rural populations suffer profound health inequities across a wide variety of diseases and conditions, including COVID-19. For example, as of June 2021, the cumulative COVID case rate in Utah per 100,000 was 10,803 among Whites vs. 17,541 among Latinos. The positivity rate was 14% among Whites vs. 24% among Latinos. Similar disparities persist across the nation for vaccination rates between urban vs. rural, high vs. low SES, and White vs. non-White populations. Low vaccination rates leave underserved populations at risk for local outbreaks, and more contagious and severe variants. Thus, interventions targeting these populations at the interplay between testing and vaccination among underserved populations are critical for pandemic control. Not only do underserved populations experience profound health inequities, but there is also a critical digital divide between high and low resource healthcare systems. Low resource settings are far less likely to adopt Health Information Technology approaches, and often do not have the capacity to implement large scale population health management (PHM) efforts utilizing data analytics and automated patient outreach. As such, research is needed utilizing targeted PHM approaches that proactively identify, reach, and navigate vulnerable patients to both increase opportunities to engage in vaccination and testing, and to address barriers to engagement. Community Health Centers (CHCs) are optimal settings for implementation of PHM interventions to increase the uptake of COVID-19 testing and vaccination among underserved populations. Eleven Utah CHC systems are participating in SCALE-UP II. Their 38 primary care clinics serve over 112,000 unique patients annually (36% Latino, 10% Native American, 63% <100% poverty level, 57% uninsured, and 42% of clinics are in rural/frontier areas). SCALE UP II is comprised of two distinct studies, the Text Message (TM) study and the Conversational Agent (CA) study. Patients will be triaged into one of two studies based on self-reported ownership of a smart phone with internet access. Patients who report not owning a smart phone with internet access will be included in the TM study. Additionally, patients who do not respond to the question regarding smart phone ownership will be included in the TM study. Patients who self-report ownership of a smart phone with internet access will be included in the CA study. SCALE-UP II: TM study will implement and evaluate practical, accessible, and scalable PHM interventions to increase COVID-19 testing and vaccine uptake based on the best evidence available, patients' specific barriers and hesitancy factors, and extensive collaboration with CHCs, AUCH, and UDHHS. This study is a 1x2 design with all patients receiving text messages as well as either type of available patient navigation. Text Messaging (TM): bidirectional text messaging to connect patients to vaccination or mailed at-home rapid test kits for use, as needed. Patient Navigation (PN): phone call from a community health worker to help address hesitancy and barriers, and to offer at-home rapid test kits. This study will examine two distinct forms of Patient Navigation: Request-PN and No PN. Each patient will be randomized to receive either Request PN or No PN. Request PN allows patients to request patient navigation by responding PERSON to a text message. Patients who are randomized to receive No PN will not be provided the opportunity to speak with a patient navigator. The primary outcome, Testing, captures whether patients actually test with the mailed at-home test kit. Secondary outcomes include: Time-To-Vaccine (time-to-event outcome) as well as several implementation outcomes including Reach-Engage Testing (proportion of patients that reply to an offer to receive an at-home rapid test kit) and Reach-Accept Testing (proportion of patients that accept an offer to receive an at-home test kit). A similar set of implementation outcomes will be measured for vaccination (i.e., Reach-Engage Vaccine and Reach-Accept Vaccine). SCALE-UP II will include a Consortium Data Reporting Unit (CDRU) consisting of a Data Manager and one member the project's biomedical informatics team. The unit will attend regular meetings and dissemination activities organized by the CDCC. The CDRU will seek guidance from the CDCC with regard to data acquisition and consent for data sharing. As required by the NIH, SCALE-UP II will collect RADx-UP Tier 1 Common Data Elements for study participants who receive an at-home COVID test through the project. These data will be collected through surveys administered one month after the participant receives their at-home test. Data will be standardized according to the data dictionary provided by the CDCC. Our CDRU will work closely with the CDCC to establish a protocol for frequency, format, and exchange of data. SCALE-UP II will share identifiable data with the CDCC and NIH for the Data Hub as well as future research. Participants who complete the survey data will first complete an informed consent process. The informed consent will be administered to the patient at the time of survey collection. Lighthouse Research and Development will conduct phone surveys to assess patient reported use of COVID-19 at-home testing (~2,300 participants) among patients who received test kits and do no respond to the online survey request. Lighthouse will send notifications (e.g., postcards, text messages, voice messages, etc.) to participants to alert them of the opportunity to complete the survey online or over the phone. Interviewers will complete up to 15 call attempts across weekday, evening, and weekend calling shifts over a one-month period to each participant. Patients will be compensated with a gift card for completing the survey. Patients will be compensated with a gift card for completing the survey.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patient-level, two-arm randomized design for Population Health Management interventions: (1) TM + No PN and (2) TM + Request PN
Masking
Participant
Masking Description
Patients will not know what intervention arm they are in.
Allocation
Randomized
Enrollment
42069 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Text Messaging (TM) + No Patient Navigation
Arm Type
Active Comparator
Arm Description
Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed. Patients will not receive patient navigation.
Arm Title
Text Message (TM) + Request (RPN)
Arm Type
Active Comparator
Arm Description
Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed. RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination.
Intervention Type
Behavioral
Intervention Name(s)
Text-Messaging (TM)
Intervention Description
Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply "yes" will receive an additional message with information about how to receive a test kit.
Intervention Type
Behavioral
Intervention Name(s)
Patient Navigation (PN)
Intervention Description
Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy. There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types.
Primary Outcome Measure Information:
Title
Testing
Description
Proportion of patients who use the at-home test out of those exposed to the intervention
Time Frame
Year 1
Secondary Outcome Measure Information:
Title
Time-To-Vaccine
Description
Time to event outcome
Time Frame
Year 1
Title
Reach-Engage Testing
Description
Proportion of patients that reply to an offer to receive an at-home rapid test kit
Time Frame
Year 1
Title
Reach-Accept Testing
Description
Proportion of patients that accept an offer to receive an at-home test kit
Time Frame
Year 1
Title
Reach-Engage Vaccine
Description
Proportion of patients that reply to an offer to receive a vaccine
Time Frame
Year 1
Title
Reach- Accept Vaccine
Description
Proportion of patients that accept an offer to receive a vaccine
Time Frame
Year 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: current patient of a participating community health center have a working cellphone, have phone number listed in existing electronic medical record at their participating clinic speak English or Spanish. Exclusion Criteria: - Minors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guilherme Del Fiol, MD PhD
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study

We'll reach out to this number within 24 hrs